Search Results

Virscio accelerates investment in advanced histology capabilities to complement in vivo translational R&D service strength

Cloud-based digital pathology platform helps CRO deliver more informed preclinical studies

Virscio, a translational research company providing definitive, actionable preclinical outcomes through the use of predictive, validated disease models, today announced publication of data that validate a nonhuman primate (NHP) model for testing drug candidates targeting retinal ischemic and neovascular diseases

RxGen, a translational research company ensuring definitive, actionable preclinical outcomes through the use of predictive, validated disease models, today announced it is rebranding as Virscio (vir’sio) to reflect substantial expansion of capabilities since inception and growth into a leading nonhuman primate preclinical research organization.

As researchers face delayed project timelines and inflated costs, industry leaders are offering an alternative option for sourcing nonhuman primates.

Biopharmaceutical companies need to look beyond the usual targets when addressing neurodegenerative disorders and also must work to correlate genetic changes to cognitive changes in patients, according to panelists at BIO’s on-demand session, “Battle of the Brains: Rethinking Neurodegenerative Disease Treatment.”

Even when manufacturing facilities are producing, widespread illness causes other delays.